Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis

Abstract

Background

The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain.

Design

We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes.

Methods

Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018).

Results

High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89–1.00, P = 0.05, I² = 13%) or absolute risk (risk difference −0.0001, 95% CI −0.0014, 0.0011, P = 0.84, I² = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82–0.93, P < 0.001, I² = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73–0.87, P < 0.001, I² = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93–1.09, P = 0.94, I² = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97–1.08, P = 0.48, I² = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality (P > 0.05).

Conclusion

The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.

Keywords

Niacin fibrates CETP inhibitors meta-analysis

Get full access to this article

View all access options for this article.

References

Castelli

Anderson

Wilson

et al.

Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992; 2: 23–28.

Sharrett

Ballantyne

Coady

et al.

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108–1113.

Gordon

Probstfield

Garrison

et al.

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.

Madsen

Varbo

Nordestgaard

. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017; 38: 2478–2486.

Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ 1971; 4: 775–784.

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 1971; 4: 767–775.

Blankenhorn

Nessim

Johnson

et al.

Beneficial effects of combined colestipol–niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233–3240.

Higgins JPT and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at http://handbook.cochrane.org.

Moher

Liberati

Tetzlaff

et al.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research ed) 2009; 339: b2535.

10.

Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (London, England) 2011; 378: 2013–2020.

11.

Schwarzer

Carpenter

Rücker

. Small-study effects in meta-analysis. In: Meta-Analysis with R, Cham: Springer International Publishing, 2015, pp. 107–141.

12.

Silverman

Ference

et al.

Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316: 1289–1297.

13.

Vickers

Altman

. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ (Clinical Research ed) 2001; 323: 1123–1124.

14.

Higgins

JPT

Altman

Gøtzsche

et al.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed) 2011; 343: d5928.

15.

DerSimonian

Laird

. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.

16.

Higgins

JPT

Thompson

Deeks

et al.

Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

17.

Egger

Davey Smith

Schneider

et al.

Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research ed) 1997; 315: 629–634.

18.

Knapp

Hartung

. Improved tests for a random effects meta-regression with a single covariate. Stat Med 2003; 22: 2693–2710.

19.

Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–381.

20.

Lincoff

Nicholls

Riesmeyer

et al.

Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017; 376: 1933–1942.

21.

Schwartz

Olsson

Abt

et al.

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089–2099.

22.

Fayad

Mani

Woodward

et al.

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (London, England) 2011; 378: 1547–1559.

23.

Luscher

Taddei

Kaski

et al.

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33: 857–865.

24.

Cannon

Shah

Dansky

et al.

Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406–2415.

25.

Nissen

Tardif

Nicholls

et al.

Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304–1316.

26.

Kastelein

van Leuven

Burgess

et al.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620–1630.

27.

Bots

Visseren

Evans

et al.

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (London, England) 2007; 370: 153–160.

28.

Barter

Caulfield

Eriksson

et al.

Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–2122.

29.

Bowman

Hopewell

Chen

et al.

Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017; 377: 1217–1227.

30.

Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke 1973; 4: 684–693.

31.

Oliver MF, Heady JA, Morris JN, et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40: 1069–1118.

32.

Carlson

Rosenhamer

. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Medica Scand 1988; 223: 405–418.

33.

Frick

Elo

Haapa

et al.

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–1245.

34.

Hanefeld

Fischer

Schmechel

et al.

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991; 14: 308–317.

35.

Elkeles

Diamond

Poulter

et al.

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641–648.

36.

Rubins

Robins

Collins

et al.

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418.

37.

BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21–27.

38.

Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (London, England) 2001; 357: 905–910.

39.

Meade

Zuhrie

Cook

et al.

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ (Clinical Research ed) 2002; 325: 1139.

40.

Keech

Simes

Barter

et al.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (London, England) 2005; 366: 1849–1861.

41.

Whitney

Krasuski

Personius

et al.

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142: 95–104.

42.

Ginsberg

Elam

Lovato

et al.

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–1574.

43.

Taylor

Sullenberger

Lee

et al.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512–3517.

44.

Guyton

Brown

Fazio

et al.

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51: 1564–1572.

45.

The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255–2267.

46.

Landray

Haynes

Hopewell

et al.

Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203–212.

47.

Baigent

Keech

Kearney

et al.

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England) 2005; 366: 1267–1278.

48.

Birjmohun

Hutten

Kastelein

et al.

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185–197.

49.

Keene

Price

Shun-Shin

et al.

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ 2014; 349: g4379.

50.

Voight

Peloso

Orho-Melander

et al.

Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet (London, England) 2012; 380: 572–580.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.84 MB